All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
TRANSLATE
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
ISHL 2022
24 Oct 2022
CONGRESS │#ISHL2022
Catherine Diefenbach @Perlmutter_CC @eaonc concludes her talk summarising outcome data from the ECOG-ACRIN study. Paediatric recruitment is ongoing
#lymphoma #lymsm #medicalcongress
Catherine Diefenbach @Perlmutter_CC @eaonc concludes her talk summarising outcome data from the ECOG-ACRIN study. Paediatric recruitment is ongoing
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS │#ISHL2022
Catherine Diefenbach @Perlmutter_CC @eaonc presents long-term phase I data from the ECOG-ACRIN Research Group exploring ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed or refractory Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
Catherine Diefenbach @Perlmutter_CC @eaonc presents long-term phase I data from the ECOG-ACRIN Research Group exploring ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed or refractory Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS │#ISHL2022
Catherine Diefenbach @Perlmutter_CC @eaonc presents long-term phase I data from the ECOG-ACRIN Research Group, exploring ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed or refractory Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
Catherine Diefenbach @Perlmutter_CC @eaonc presents long-term phase I data from the ECOG-ACRIN Research Group, exploring ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed or refractory Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS │#ISHL2022
Alison Moskowitz from
@MSKCancerCenter concludes her presentation on the Phase II pembro-GVD study, describing high CR rates, durable responses and manageable toxicities, and need to consider optimal salvage therapies if patients relapse
#lymphoma #lymsm
Alison Moskowitz from
@MSKCancerCenter concludes her presentation on the Phase II pembro-GVD study, describing high CR rates, durable responses and manageable toxicities, and need to consider optimal salvage therapies if patients relapse
#lymphoma #lymsm
24 Oct 2022
CONGRESS │#ISHL2022
Alison Moskowitz from @MSKCancerCenter describes outcome and safety data from the pembro-GVD study, including engraftment syndrome
#lymphoma #lymsm #medicalcongress
Alison Moskowitz from @MSKCancerCenter describes outcome and safety data from the pembro-GVD study, including engraftment syndrome
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS │#ISHL2022 Alison Moskowitz from @MSKCancerCentrer presents phase II data demonstrating high efficacy and durability using pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin for the 2nd line treatment of R/R HL #lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS │#ISHL2022
Alison Moskowitz from @MSKCancerCenter concludes her presentation on the Phase II pembro-GVD study, describing high CR rates, durable responses and manageable toxicities, and the need to consider optimal salvage therapies if patients relapse
#lymphoma #lymsm
Alison Moskowitz from @MSKCancerCenter concludes her presentation on the Phase II pembro-GVD study, describing high CR rates, durable responses and manageable toxicities, and the need to consider optimal salvage therapies if patients relapse
#lymphoma #lymsm
24 Oct 2022
CONGRESS │#ISHL2022
Alison Moskowitz from @MSKCancer Centre describes outcome and safety data from the pembro-GVD study, including engraftment syndrome
#lymphoma #lymsm #medicalcongress
Alison Moskowitz from @MSKCancer Centre describes outcome and safety data from the pembro-GVD study, including engraftment syndrome
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
@AnnaSureda5 presents outcome data from the BRESELIBET trial
#lymphoma #lymsm #medicalcongress
@AnnaSureda5 presents outcome data from the BRESELIBET trial
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
@AnnaSureda5 presents safety data from the BRESELIBET trial, demonstrating good tolerability in both trial arms
#lymphoma #lymsm #medicalcongress
@AnnaSureda5 presents safety data from the BRESELIBET trial, demonstrating good tolerability in both trial arms
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
@AnnaSureda5 presents exclusion criteria, and recruitment information from the BRESELIBET trial, with data on patient characteristics
#lymphoma #lymsm #medicalcongress
@AnnaSureda5 presents exclusion criteria, and recruitment information from the BRESELIBET trial, with data on patient characteristics
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
@AnnaSureda5 presents the study design and rationale of the BRESELIBET trial – BRESHAP vs ESHAP for the treatment of classical R/R HL
#lymphoma #lymsm #medicalcongress
@AnnaSureda5 presents the study design and rationale of the BRESELIBET trial – BRESHAP vs ESHAP for the treatment of classical R/R HL
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS │#ISHL2022
@SFBarringtonKCL, @DocHutchings and Carsten Kobe lead a panel presenting output from a workshop on the Deauville five-point scale, including MTV assessment and improving the accuracy of baseline PET assessment
#lymphoma #lymsm #medicalcongress
@SFBarringtonKCL, @DocHutchings and Carsten Kobe lead a panel presenting output from a workshop on the Deauville five-point scale, including MTV assessment and improving the accuracy of baseline PET assessment
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS │#ISHL2022
@graham74GC from @OxfordHaem concludes his talk with a discussion of epigenetic targeting and CDK9 inhibition for the treatment of R/R HL
#lymphoma #lymsm
@graham74GC from @OxfordHaem concludes his talk with a discussion of epigenetic targeting and CDK9 inhibition for the treatment of R/R HL
#lymphoma #lymsm
24 Oct 2022
CONGRESS │#ISHL2022
@graham74GC from @OxfordHaem discusses bispecific therapies for the treatment of HL, including favezelimab and AFM13
#lymphoma #lymsm
@graham74GC from @OxfordHaem discusses bispecific therapies for the treatment of HL, including favezelimab and AFM13
#lymphoma #lymsm
24 Oct 2022
CONGRESS │#ISHL2022
@graham74GC from @OxfordHaem presents efficacy and safety data on camidanlumab tesirine, in heavily pretreated patients who have failed brentuximab and received a checkpoint inhibitor, and challenges in further trial design
#lymphoma #lymsm
@graham74GC from @OxfordHaem presents efficacy and safety data on camidanlumab tesirine, in heavily pretreated patients who have failed brentuximab and received a checkpoint inhibitor, and challenges in further trial design
#lymphoma #lymsm
24 Oct 2022
CONGRESS │#ISHL2022
@graham74GC from @OxfordHaem presents his expert opinion on novel agents for the treatment of R/R HL, including trial heterogeneity, toxicity and outcome data
#lymphoma #lymsm #medicalcongress
👇To find out more visit @Lymphoma here https://t.co/vzK5png6XP
@graham74GC from @OxfordHaem presents his expert opinion on novel agents for the treatment of R/R HL, including trial heterogeneity, toxicity and outcome data
#lymphoma #lymsm #medicalcongress
👇To find out more visit @Lymphoma here https://t.co/vzK5png6XP
24 Oct 2022
CONGRESS │#ISHL2022
@CraigMoskMD from @UMiamiHealth discusses the AETHERA study, BV salvage and BeGEV therapy
#lymphoma #lymsm #medicalcongress
@CraigMoskMD from @UMiamiHealth discusses the AETHERA study, BV salvage and BeGEV therapy
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS │#ISHL2022
@CraigMoskMD from @UMiamiHealth continues his talk discussing check point inhibitors, pembro-GVD and NICE regimen for the treatment of Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
@CraigMoskMD from @UMiamiHealth continues his talk discussing check point inhibitors, pembro-GVD and NICE regimen for the treatment of Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS │#ISHL2022
@CraigMoskMD from @UMiamiHealth delivers an update on optimal and current treatments for patients with HL - is functional imaging still the most significant determinant of outcome?
#lymphoma #lymsm #medicalcongress
@CraigMoskMD from @UMiamiHealth delivers an update on optimal and current treatments for patients with HL - is functional imaging still the most significant determinant of outcome?
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS │#ISHL2022
@CraigMoskMD from @UMiamiHealth delivers an update on optimal and current treatments for patients with HL at first relapse
👇Find out more here @LymphomaHub https://t.co/TrXMJEWXd7
#lymphoma #lymsm #medicalcongress
@CraigMoskMD from @UMiamiHealth delivers an update on optimal and current treatments for patients with HL at first relapse
👇Find out more here @LymphomaHub https://t.co/TrXMJEWXd7
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
Christian Steidl from @BCCancer concludes discussing genetic axis and spatial patterns in Hodgkin Lymphoma as putative prognostic markers
#lymphoma #lymsm #medicalcongress
Christian Steidl from @BCCancer concludes discussing genetic axis and spatial patterns in Hodgkin Lymphoma as putative prognostic markers
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
Christian Steidl from @BCCancer explains how single cell biology, and understanding transcriptomes is relevant to the treatment of HL
#lymphoma #lymsm #medicalcongress
Christian Steidl from @BCCancer explains how single cell biology, and understanding transcriptomes is relevant to the treatment of HL
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
Christian Steidl from @BCCancer describes RNA expression profiles in Hodgkin Lymphoma cells including LAG3 and FOXP3, alongside Treg cell markers
#lymphoma #lymsm #medicalcongress
Christian Steidl from @BCCancer describes RNA expression profiles in Hodgkin Lymphoma cells including LAG3 and FOXP3, alongside Treg cell markers
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
Christian Steidl from @BCCancer presents the latest research on single cell transcriptomics and technologies in Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
Christian Steidl from @BCCancer presents the latest research on single cell transcriptomics and technologies in Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
Sven Borchmann from @UniCologne describes subsets and genetic clusters of Hodgkin Lymphoma as identified on liquid biopsy, including high mutation burden and phenotypic considerations
#lymphoma #lymsm #medicalcongress
Sven Borchmann from @UniCologne describes subsets and genetic clusters of Hodgkin Lymphoma as identified on liquid biopsy, including high mutation burden and phenotypic considerations
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
Sven Borchmann from @UniCologne presents his expert opinion on the utility of liquid biopsy in Hodgkin Lymphoma, including predicting poorer outcomes in some populations
#lymphoma #lymsm #medicalcongress
Sven Borchmann from @UniCologne presents his expert opinion on the utility of liquid biopsy in Hodgkin Lymphoma, including predicting poorer outcomes in some populations
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
Sven Borchmann from @UniCologne presents his expert opinion on how liquid biopsy can assist the biological classification of HL,
#lymphoma #lymsm #medicalcongress
Sven Borchmann from @UniCologne presents his expert opinion on how liquid biopsy can assist the biological classification of HL,
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
Peter Borchmann from @UniCologne presents further data from the phase III HD21 Trial, exploring BrECADD for the treatment of Hodkin Lymphoma
#lymphoma #lymsm #medicalcongress
Peter Borchmann from @UniCologne presents further data from the phase III HD21 Trial, exploring BrECADD for the treatment of Hodkin Lymphoma
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
Peter Borchmann from @UniCologne presents results from the phase III HD21 Trial, with new data on treatment related morbidity in patients with classical HL
#lymphoma #lymsm #medicalcongress
Peter Borchmann from @UniCologne presents results from the phase III HD21 Trial, with new data on treatment related morbidity in patients with classical HL
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
Martin Dreyling (HCP, @LMU_Uniklinikum), Jack Richardson (Patient) and Sarah Wells (Clinical Nurse Specialist, @sazza_g) discuss current treatments for advanced HL and the priorities of patients
Cure foremost..?
Who wants ABVD vs BEACOPP?
#lymphoma #lymsm
Martin Dreyling (HCP, @LMU_Uniklinikum), Jack Richardson (Patient) and Sarah Wells (Clinical Nurse Specialist, @sazza_g) discuss current treatments for advanced HL and the priorities of patients
Cure foremost..?
Who wants ABVD vs BEACOPP?
#lymphoma #lymsm
24 Oct 2022
CONGRESS│#ISHL2022
Peter Borchmann from @UniCologne concludes his expert opinion on selecting PET-adapted escalated BEACOPP for the treatment of advanced stage Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
Peter Borchmann from @UniCologne concludes his expert opinion on selecting PET-adapted escalated BEACOPP for the treatment of advanced stage Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
24 Oct 2022
CONGRESS│#ISHL2022
Peter Borchmann from @UniCologne considers and explains the reasons for selecting PET-adapted escalated BEACOPP for the treatment of advanced stage Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
Peter Borchmann from @UniCologne considers and explains the reasons for selecting PET-adapted escalated BEACOPP for the treatment of advanced stage Hodgkin Lymphoma
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@DrAEvens from @RutgersCancer shares a final summary on the management of older patients with Hodgkin Lymphoma
#lymphoma #lymsm
@DrAEvens from @RutgersCancer shares a final summary on the management of older patients with Hodgkin Lymphoma
#lymphoma #lymsm
23 Oct 2022
CONGRESS│#ISHL2022
@DrAEvens from @RutgersCancer
discusses recent and novel clinical trials for older patients with #lymphoma
#lymsm #medicalcongress
@DrAEvens from @RutgersCancer
discusses recent and novel clinical trials for older patients with #lymphoma
#lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@DrAEvens from @RutgersCancer discusses historical considerations and outcomes of Hodgkin Lymphoma treatment in older patients #lymphoma #lymsm #medicalcongress
@DrAEvens from @RutgersCancer discusses historical considerations and outcomes of Hodgkin Lymphoma treatment in older patients #lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@BroeckelmannPJ from @UniCologne offers his expert opinion on PD1 blockade for the treatment of HL - what do we need to consider?
#lymphoma #lymsm
@BroeckelmannPJ from @UniCologne offers his expert opinion on PD1 blockade for the treatment of HL - what do we need to consider?
#lymphoma #lymsm
23 Oct 2022
CONGRESS│#ISHL2022
@BroeckelmannPJ from @UniCologne discusses the benefits/challenges of PD1 blockade in the frontline treatment of HL, including hurdles to cure such as age, treatment risk-benefit, tumour microenvironment and secondary resistance
#lymphoma #lymsm
@BroeckelmannPJ from @UniCologne discusses the benefits/challenges of PD1 blockade in the frontline treatment of HL, including hurdles to cure such as age, treatment risk-benefit, tumour microenvironment and secondary resistance
#lymphoma #lymsm
23 Oct 2022
CONGRESS│#ISHL2022
@graham74GC from @OxfordHaem concludes his presentation on the future of PD-1 inhibitors for the treatment of HL, including the future role of ctDNA and TARC
#lymphoma #lymsm #medicalcongress
@graham74GC from @OxfordHaem concludes his presentation on the future of PD-1 inhibitors for the treatment of HL, including the future role of ctDNA and TARC
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@graham74GC from @OxfordHaem discusses current considerations and advances in the use of PD1 inhibitors for the treatment of HL, including the potential for reduced, or even abolished chemotherapy
#lymphoma #lymsm #medicalcongress
@graham74GC from @OxfordHaem discusses current considerations and advances in the use of PD1 inhibitors for the treatment of HL, including the potential for reduced, or even abolished chemotherapy
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
Christian Steidl from @BCCancer presents his expert vision on challenges in translation research in HL, including tumour microenvironment, single cell resolution, genomic analysis and age related heterogeneity
#lymphoma #lymsm #medicalcongress
Christian Steidl from @BCCancer presents his expert vision on challenges in translation research in HL, including tumour microenvironment, single cell resolution, genomic analysis and age related heterogeneity
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
John Timmerman from @UCLAHealth presents adverse event and efficacy data from the safety and dose expansion phase of NCT03598608, exploring favezelimab and pembrolizumab in patients with classical R/R HL
#lymphoma #lymsm #medicalcongress
John Timmerman from @UCLAHealth presents adverse event and efficacy data from the safety and dose expansion phase of NCT03598608, exploring favezelimab and pembrolizumab in patients with classical R/R HL
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
John Timmerman from @UCLAHealth presents adverse event and efficacy data from the safety and dose expansion phase of NCT03598608, exploring favezelimab and pembrolizumab in patients with classical R/R HL
#lymphoma #lymsm #medicalcongress
John Timmerman from @UCLAHealth presents adverse event and efficacy data from the safety and dose expansion phase of NCT03598608, exploring favezelimab and pembrolizumab in patients with classical R/R HL
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
John Timmerman from @UCLAHealth presents data from the safety and dose expansion phase of NCT03598608, treating patients with R/R cHL who are anti-PD-1 naïve
For further trial info see here 👉 https://t.co/XPpCqgn1tA
#lymphoma #lymsm #medicalcongress
John Timmerman from @UCLAHealth presents data from the safety and dose expansion phase of NCT03598608, treating patients with R/R cHL who are anti-PD-1 naïve
For further trial info see here 👉 https://t.co/XPpCqgn1tA
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
Ryan Lynch from @UWMedicine presents the latest data on ctDNA for the assessment of tumour response in patients with classical HL treated with pembrolizumab and chemotherapy, considering PET and current imaging
#lymphoma #lymsm #medicalcongress
Ryan Lynch from @UWMedicine presents the latest data on ctDNA for the assessment of tumour response in patients with classical HL treated with pembrolizumab and chemotherapy, considering PET and current imaging
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
Stephen Ansell from @MayoClinic describes some of the challenges in our knowledge of Hodgkin Lymphoma, that have emerged since ISHL11 (2018)
#lymphoma #lymsm #medicalcongress
Stephen Ansell from @MayoClinic describes some of the challenges in our knowledge of Hodgkin Lymphoma, that have emerged since ISHL11 (2018)
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
Stephen Ansell from @MayoClinic describes progress in Hodgkin Lymphoma, since ISHL11 (2018)
#lymphoma #lymsm #medicalcongress
Stephen Ansell from @MayoClinic describes progress in Hodgkin Lymphoma, since ISHL11 (2018)
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
Stephen Ansell from @MayoClinic describes progress, and new findings and challenges in Hodgkin Lymphoma that have emerged since ISHL11 (2018)
#lymphoma #lymsm #medicalcongress
Stephen Ansell from @MayoClinic describes progress, and new findings and challenges in Hodgkin Lymphoma that have emerged since ISHL11 (2018)
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@irenebisaoli from
@ufrjconcludes her presentation on data from the Brazilian Prospective HL Registry with reference to the impact of socioeconomic status on mortality rate, and conclusions on overall treatment outcomes #lymphoma #lymsm #medicalcongress
@irenebisaoli from
@ufrjconcludes her presentation on data from the Brazilian Prospective HL Registry with reference to the impact of socioeconomic status on mortality rate, and conclusions on overall treatment outcomes #lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@irenebisaoli from @ufrj presents data from the Brazilian Prospective HL Registry, including ABVD as first line, use of bleomycin, mortality during treatment and lung toxicity in patients being treated for HL #lymphoma #lymsm #medicalcongress
@irenebisaoli from @ufrj presents data from the Brazilian Prospective HL Registry, including ABVD as first line, use of bleomycin, mortality during treatment and lung toxicity in patients being treated for HL #lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@irenebisaoli from @ufrj presents the latest update from the Brazilian Prospective HL Registry on treatment patterns and outcomes for patients aged 60 years and older #lymphoma #lymsm #medicalcongress
@irenebisaoli from @ufrj presents the latest update from the Brazilian Prospective HL Registry on treatment patterns and outcomes for patients aged 60 years and older #lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@irenebisaoli from @ufrj concludes her presentation of data from the Brazilian Prospective HL Registry with reference to the impact of socioeconomic status on mortality rate, and conclusion on overall outcome
#lymphoma #lymsm #medicalcongress
@irenebisaoli from @ufrj concludes her presentation of data from the Brazilian Prospective HL Registry with reference to the impact of socioeconomic status on mortality rate, and conclusion on overall outcome
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@irenebisaoli from @ufrj describes data from the Brazilian Prospective HL Registry, including ABVD as first line, use of bleomycin, mortality during treatment and lung toxicity in patients being treated for HL
#lymphoma #lymsm #medicalcongress
@irenebisaoli from @ufrj describes data from the Brazilian Prospective HL Registry, including ABVD as first line, use of bleomycin, mortality during treatment and lung toxicity in patients being treated for HL
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@irenebisaoli from @ufrj presents the latest update from the Brazilian Prospective HL Registry on treatment patterns and outcomes for patients aged 60 years and older
#lymphoma #lymsm #medicalcongress
@irenebisaoli from @ufrj presents the latest update from the Brazilian Prospective HL Registry on treatment patterns and outcomes for patients aged 60 years and older
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@JenicaUpshaw from @TuftsMedicalCtr concludes her talk discussing study limitations, improvements in HL treatments and conclusion from the study
#lymphoma #lymsm #medicalcongress
@JenicaUpshaw from @TuftsMedicalCtr concludes her talk discussing study limitations, improvements in HL treatments and conclusion from the study
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@JenicaUpshaw from @TuftsMedicalCtr describes the trial design of the featured study exploring heart failure in older patients being treated for HL, latest data and influence of pre-existing heart failure
#lymphoma #lymsm #medicalcongress
@JenicaUpshaw from @TuftsMedicalCtr describes the trial design of the featured study exploring heart failure in older patients being treated for HL, latest data and influence of pre-existing heart failure
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
Ninja Övergaard from @IgpUu discusses AVD as the 1st line treatment of older patients with classic HL
#lymphoma #lymsm #medicalcongress
Ninja Övergaard from @IgpUu discusses AVD as the 1st line treatment of older patients with classic HL
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
Alex Fosså from @Oslounivsykehus presents a summary of the #ISHL2022 Workshop (22/10/2022) on innovations in Hodgkin Lymphoma treatment for older patients #lymphoma #lymsm #medicalcongress
Alex Fosså from @Oslounivsykehus presents a summary of the #ISHL2022 Workshop (22/10/2022) on innovations in Hodgkin Lymphoma treatment for older patients #lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@DrAEvans from @RutgersCancer closes with his final thoughts on the management of patients with #lymphoma, including effective geriatric measures and assessments, and the importance of antracyclines
#lymsm #medicalcongress
@DrAEvans from @RutgersCancer closes with his final thoughts on the management of patients with #lymphoma, including effective geriatric measures and assessments, and the importance of antracyclines
#lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@DrAEvans from @RutgersCancer discusses recent and novel clinical trials for older patients with #lymphoma
#lymphoma #lymsm #medicalcongress
@DrAEvans from @RutgersCancer discusses recent and novel clinical trials for older patients with #lymphoma
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@DrAEvans from @RutgersCancer
Efficacy and outcome data from recent clinical studies in patients with #lymphoma, including the ECHELON-1 trial and patients treated with bendustamine
#lymphoma #lymsm #medicalcongress
@DrAEvans from @RutgersCancer
Efficacy and outcome data from recent clinical studies in patients with #lymphoma, including the ECHELON-1 trial and patients treated with bendustamine
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@DrAEvans from @RutgersCancer discusses historical considerations and outcomes Hodgkin Lymphoma treatment in older patients
#lymphoma #lymsm #medicalcongress
@DrAEvans from @RutgersCancer discusses historical considerations and outcomes Hodgkin Lymphoma treatment in older patients
#lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@DrRaulCordoba from @Hospital_FJD explains how patients with Hodgkin Lymphoma can be included in decision making, and what the patient journey can look like #lymphoma #lymsm #medicalcongress
@DrRaulCordoba from @Hospital_FJD explains how patients with Hodgkin Lymphoma can be included in decision making, and what the patient journey can look like #lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@DrRaulCordoba from @Hospital_FJD share his experience on importance of assessing performance status and activities of daily living in patients with lymphoma. Under treating fit patients can be as significant as over treating frail ones! #lymphoma #lymsm
@DrRaulCordoba from @Hospital_FJD share his experience on importance of assessing performance status and activities of daily living in patients with lymphoma. Under treating fit patients can be as significant as over treating frail ones! #lymphoma #lymsm
23 Oct 2022
CONGRESS│#ISHL2022
@DrRaulCordoba from @Hospital_FJD explores the difficulty of assessing older patients for HL treatment, including the 8 domains of geriatric assessment, especially comorbidities #lymphoma #lymsm #medicalcongress
@DrRaulCordoba from @Hospital_FJD explores the difficulty of assessing older patients for HL treatment, including the 8 domains of geriatric assessment, especially comorbidities #lymphoma #lymsm #medicalcongress
23 Oct 2022
CONGRESS│#ISHL2022
@DrRaulCordoba from @Hospital_FJD discusses challenges in the management of older patients with Hodgkin Lymphoma. How does frailty increase with age?
#lymphoma #lymsm #medicalcongress
@DrRaulCordoba from @Hospital_FJD discusses challenges in the management of older patients with Hodgkin Lymphoma. How does frailty increase with age?
#lymphoma #lymsm #medicalcongress
22 Oct 2022
CONGRESS #ISHL2022 | @AndreaGallamin3 at Lacassagne cancer center presented phase II trial design and preliminary results of the RAFTING trial in patients with non-bulky Hodgkin lymphoma. N=66 #lymsm #lymphoma
22 Oct 2022
CONGRESS #ISHL2022 |@becshakir @UniofOxford discussed the importance and strategies of shared decision-making between patients with Hodgkin lymphoma and clinicians and its impact on the treatment in patients with Hodgkin lymphoma #lymsm #lymphoma
22 Oct 2022
CONGRESS #ISHL2022 | John Radford @OfficialUoM discussed standard and optimized treatment strategies for early-stage Hodgkin lymphoma to maximize disease elimination and minimize late treatment toxicities #lymsm #lymphoma
<span> </span>
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?